- Amivantamab plus chemotherapy vs chemotherapy as a first-line treatment among Asian patients with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): PAPILLON subgroup analysisZhou, C.; Tang, K.; Liu, B.; Kim, S-W.; Kitazono, S.; Ono, A.; Thiagarajan, M.; Hung, J-Y.; Boyer, M.; Xie, J.; Bhattacharya, A.; Baig, M.; Agrawal, T.; Knoblauch, R. E.; Cho, B. C.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
- Brief Report: Immunochemotherapy in Five Patients with EGFR Exon 20 Insertion Advanced Lung AdenocarcinomaPeng, K.; Wang, H.; Gao, Y.; Li, X.; Gao, Q.; Zhang, S.; Yang, J.
- Safety and preliminary efficacy of YK-029A, a novel EGFR TKI, in patients with advanced NSCLC harboring ex20ins, T790M or rare mutationsDuan, Jianchun; Zhao, Jun; Zhang, Li; Liu, Baogang; Ren, Xiubao; Li, Mingjun; Shen, Bo; Miao, Liyun; Dai, Xiumei; Pan, Yueyin; Li, Yupin; Yao, Yu; Yang, Kunyu; Wu, Lin; Zhou, Chengzhi; Yu, Qitao; Xie, Yanyan; Zeng, Shan; Wang, JieAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
会议论文
Efficacy of various types of chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 in-frame insertions.
18阅读
